When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

Beyfortus is not known to interact with other medications, herbs, supplements, foods, or alcohol. The manufacturer of Beyfortus didn’t look at interactions in studies of the drug.

This Tuesday, the Health Ministry will begin training medical teams ahead of a historic campaign to protect all Israeli ...

The new shot, which goes by the brand name Beyfortus, slashed infants’ risk of being hospitalized for RSV by 80% in clinical trials. It promised to be a game-changer for the youngest patients.

In July, the FDA approved Beyfortus and the CDC recommended it for children under 8 months of age who are entering their first respiratory virus season. The immunization is also recommended for ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

The CDC and FDA have approved the Beyfortus antibody shot, from drugmakers AstraZeneca and Sanofi, to prevent respiratory syncytial virus in babies from birth to 8 months old, or in children up to ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...